• Transcripta Bio

  Participated · Series B · Jul 2026

  Transcripta Bio operates a closed-loop discovery engine that uses transcriptomic signature matching to find drug candidates whose molecular signatures invert patient-derived disease signatures. Its platform comprises a Disease Signature Atlas built from patient single-cell RNA sequencing data, a Drug-Gene Atlas mapping transcriptomic responses of compounds, and Conductor AI, a machine learning system trained on more than one billion gene responses. The company’s pipeline spans four programs across Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), Autism Spectrum Disorder (ASD), and Huntington’s Disease (HD). Transcripta is advancing IND-enabling studies and preparing clinical work for its ASD and FSHD programs. The company is based in Palo Alto, California. It has raised $24 million since its Series A to accelerate progression of its pipeline toward human clinical trials.

• Enveda Biosciences

  Participated · Series B · Jun 2024

  Enveda is a clinical-stage biotechnology company that learns from life’s chemistry to create small-molecule therapeutics using AI-powered metabolomics and a proprietary chemical sequencer. The platform makes previously inaccessible natural chemistry searchable and uses automation to map therapeutic properties at high throughput. Enveda says it delivers 12+ development candidates 4× faster and 10× cheaper than industry averages and has built one of the world’s largest collections of natural samples. Its pipeline includes sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program. ENV-294, the lead program, is a first-in-class oral anti-inflammatory small molecule discovered on the platform and has moved into a Phase 1b trial after favorable Phase 1a results; Enveda has enrolled the first patient. The company recently raised additional capital and added industry veteran Dr. Mikael Dolsten to its board to support clinical advancement across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and other indications. Enveda harnesses AI-powered tools to identify and characterize molecules produced by living organisms, building a database of chemical biodiversity it calls the library of life. Its platform integrates computational methods with deep chemical and biological insights to uncover novel mechanisms of action and drug candidates. The company has advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, into clinical trials and highlights the potential for a safe, effective oral therapy in immunology and inflammation. Enveda plans to expand its clinical pipeline in 2025 and further enhance its AI-driven discovery capabilities. The company frames its approach as metabolite-driven drug development aimed at delivering medicines faster by learning from evolved solutions in nature. Enveda is a biotechnology company that uses an AI-powered platform combining metabolomics, machine learning, and automated high-throughput laboratory workflows to translate natural compounds into drug candidates. Its platform has characterized the structure and function of over 1 million natural compounds, creating the largest known natural product dataset custom-built for modern drug discovery. The company says this approach answers what molecules are and what they do at scale and enables discovery roughly four times faster than historical averages. Enveda’s pipeline includes 10 Development Candidates across immunology & inflammation, obesity, fibrosis, and neurosensory indications. The company recently received IND clearance for ENV-294, which entered Phase I at the end of October. The new funding will support multiple clinical catalysts in 2025 and 2026 and further investment in the platform and discovery programs. Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, combines AI with ethnobotanical knowledge to identify medicinal molecules from plants. The company has assembled a database of about 38,000 medicinal plants linked to roughly 12,000 diseases and symptoms. Using a transformer model that deciphers the "chemical language" of whole samples, Enveda prioritizes sets of molecules for development rather than studying single compounds in isolation. That platform has produced near-term assets: two drugs (one for skin conditions including eczema, and one for inflammatory bowel diseases) are expected to enter clinical trials later this year. Financially, the company has raised capital that totals $230 million to date and plans to pursue a Series C after the start of those clinical trials. Enveda builds a proprietary platform that combines large language models, metabolomics, and robotics to create a high-resolution chemical map of nature and search nature’s chemical space for drug discovery. The platform addresses long-standing obstacles in natural product drug development, including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. Enveda pairs this technology with experienced drug hunters and data scientists to advance platform-derived molecules. The company plans to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. Financially, Enveda has been raising growth capital to advance its pipeline and platform and recently completed additional financing to support clinical progress. For more information, Enveda directs readers to envedabio.com.

• Reken

  Participated · Seed · Feb 2024

  Reken is a San Francisco-based AI and cybersecurity company building AI products and a platform to protect against generative AI threats. Founded in January by Shuman Ghosemajumder and Rich Griffiths, the firm focuses on defending against deepfake social engineering and autonomous fraud. Ghosemajumder previously served as Google’s Global Head of Product for Trust & Safety, Head of AI at F5, and CTO at Shape Security. Reken raised $10M in Seed funding led by Greycroft and FPV Ventures with participation from Firebolt Ventures, Fika Ventures, Omega Venture Partners, Homebrew, and JAZZ Venture Partners, plus investments from Jon Steinback and Vishal Vasishth. The company will use the funds for core research and development to build new AI technologies and products aimed at mitigating generative AI threats. Greycroft partner Marcie Vu, who helped lead Google’s IPO, joined Reken’s board.

• Tomato.ai

  Participated · Equity · Jan 2024

  Tomato.ai develops a PC application that offers Accent Softening (currently in beta) and a generative-AI Noise Cancellation feature. Accent Softening installs on a PC and works with communications platforms such as Zoom, Teams, Meet, and other VoIP solutions, aiming to embrace accents while improving clarity. Noise Cancellation recreates a person’s voice while removing background noise and is delivered through the same application. The company raised a $2.1M+ extension to its seed round and says it will use the proceeds to expand operations and further product development. Tomato.ai is led by CEO Ofer Ronen and CTO James Fan and is based in Danville, California. No revenue or user metrics were provided in the article. Tomato.ai builds a real-time AI platform that smooths contact-center agents' accents while keeping the speakers' original voice identity. The solution works out of the box without per-agent training and removes the need for complicated transcriptions. The company has worked with multiple design partners, from very large outsourcing firms with tens of thousands of agents to providers with about a thousand agents, with deployments in countries such as India, the Philippines and Pakistan. Its research team — in which more than 90% of members have an accent — did foundational work in speech generation and helped invent the field of accent smoothing. Co-founders Ofer Ronen (CEO) and James Fan (CTO) are U.S.-based serial entrepreneurs who previously worked on contact-center AI at Google. Tomato.ai says the product aims to improve comprehension, expand access to higher-paying jobs, and the company is hiring machine-learning engineers and speech-generation researchers to scale across languages and dialects. The company recently closed a $10M financing round to support its launch and R&D efforts.

• HerMD

  Led · Series A · Jul 2023

  HerMD offers comprehensive women's healthcare both in-person and virtually, with medical services billed through insurance and Medicare. Appointments average 20–60 minutes, and the company also provides aesthetic services such as facial injectables and body treatments. To address provider training gaps, HerMD created HerMD University, which uses proprietary algorithms of care plus conferences and monthly meetings to train clinicians. The company operates clinics in Cincinnati, Franklin, Tennessee and Carmel, Indiana and has around 20 providers; it consistently sees a waitlist of approximately 500 patients leading up to clinic openings. Founder and chief medical officer Dr. Somi Javaid opened the first location in 2015; Kathy McAleer became CEO in 2022. With the new funding, HerMD plans to expand brick-and-mortar locations (including its first New York City-area site and a second Nashville-area clinic), grow its team, develop virtual services and HerMD University, launch mental-health services, introduce e-commerce and physician-curated products, and invest in sexual-health and menopause technologies. HerMD is a minority, female-founded women’s health startup led by founder and chief medical officer Dr. Somi Javaid, an OBGYN. The company operates two centers in Cincinnati and Crescent Springs, Kentucky, and has attracted patients from 30 states and Canada. HerMD provides specialized sexual health and menopause services, with providers who have specialty training and offerings that include procedures such as Botox for vaginismus. The company accepts insurance for gynecologic procedures and offers discounted self-pay options. HerMD plans to expand with new physical centers and to roll out telehealth to increase access to sexual health and menopause care.

No current team members are available.